lyratherapeutics.com (LYRA): Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics, Inc. (LYRA) remains resilient to economic fluctuations, as demand for medtech is stable. Historical PEG ratio dynamics demonstrate the market's reaction to fundamental reliability, where the value of 0.00 reflects the metric's balance. The business relies on external contractors for trials and manufacturing, while simultaneously facing pressure from industry behemoths and generic manufacturers.

LYRA - Lyra Therapeutics Inc. PEG Multiple over the range 07/04/2022 - 03/28/2026

Metric breakdowns and analytics for Lyra Therapeutics (LYRA)

- share price and consensus valuation forecast:
Fundamental company analysis:Lyra Therapeutics, Inc. LYRA
Mass-produced product of lyratherapeutics.com

Lyra Therapeutics, Inc. (LYRA) is developing an innovative non-invasive drug delivery system for the treatment of ENT diseases in the US. This indicator compares the P/E market multiple with earnings dynamics to determine the fairness of the current share price. Values below one signal that the asset is undervalued relative to its expansion. Analyzing the ratio between the P/E and the company's growth rates helps identify a business slowdown in a timely manner. This chart makes it easy to determine the risk of overpaying for the issuer's technological potential.

Who Lyra Therapeutics, Inc. competes with

HLN - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Kenvue Inc KVUE|Verona Pharma (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|Ligand - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company - Growth-Adjusted Payback Ratio|ALVO (Alvotech S.A.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate liquidia.com LQDA|Price/Earnings to Growth Ratio Galapagos (GLPG)|ANIP (ANI Pharmaceuticals, Inc.) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Afrezza MNKD|PEG Multiple Amphastar Corp AMPH|Pacira Corp - PEG Multiple|Growth-Adjusted Payback Ratio SPRY (ars-pharma.com)|TBPH: PEG Multiple|Aquestive Therapeutics, Inc. (AQST) - PEG Multiple|SCPH (scpharmaceuticals.com) - PEG Multiple|TECX (tectonictx.com) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple TNXP (Tonix Pharmaceuticals Holding Corp.)|PEG Multiple SXT China (SXTC)|eupraxiapharma.com - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BHST|invizyne.com - PEG Multiple|Growth-Adjusted Payback Ratio ORMP (Oramed Pharmaceuticals Inc.)|ENTX: PEG Multiple|MindWalk Holdings Inc. (HYFT) - PEG Multiple|Price/Earnings to Growth Ratio ABVC BioPharma|Growth-Adjusted P/E Ratio CPIX (Cumberland Pharmaceuticals Inc.)|PEG Multiple QNTM|Growth-Adjusted Market Cap to Net Income FibroGen Corporation|PEG Multiple TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Inc) - Market Cap to Earnings and Growth Ratio|SNYR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio RLYB (Rallybio)|LEXX: PEG Multiple|Price/Earnings to Growth Multiple Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - PEG Multiple|Price/Earnings to Growth Ratio APM|PEG Multiple IBO|Growth-Adjusted Market Cap to Net Income TNF Pharmaceuticals, Inc.|PEG Multiple YCBD (cbdMD, Inc.)|PRFX (PainReform Corp) - Market Cap to Earnings and Growth Ratio|CYTO: Price/Earnings to Growth Multiple|LIPO - PEG Multiple|OptiNose, Inc. (OPTN) - Price/Earnings to Growth Ratio|PIRS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Procaps|Price/Earnings to Growth Multiple Petros (PTPI)|Price/Earnings to Growth Ratio Qilian International Corp (QLI)|PEG Multiple acelyrin.com (SLRN)|PEG Multiple TFFP (TFF Pharmaceuticals)